Long-Term Quantitative Evaluation of Muscle and Bone Wasting Induced by Botulinum Toxin in Mice Using Microcomputed Tomography

2017 ◽  
Vol 102 (6) ◽  
pp. 695-704 ◽  
Author(s):  
Hélène Libouban ◽  
Claude Guintard ◽  
Nicolas Minier ◽  
Eric Aguado ◽  
Daniel Chappard
2008 ◽  
Vol 35 (S 01) ◽  
Author(s):  
K Kollewe ◽  
S Baloush ◽  
K Krampfl ◽  
H Bigalke ◽  
R Dengler ◽  
...  

2021 ◽  
Author(s):  
Sara Alipour ◽  
Carina Pick ◽  
Stefanie Jansen ◽  
Svenja Rink ◽  
Jens Peter Klußmann ◽  
...  

2002 ◽  
Vol 17 (6) ◽  
pp. 1288-1293 ◽  
Author(s):  
G-Y.R. Hsiung ◽  
S.K. Das ◽  
R. Ranawaya ◽  
A.-L. Lafontaine ◽  
O. Suchowersky

2013 ◽  
Vol 11 (8) ◽  
pp. 657
Author(s):  
Zoltan Mari ◽  
Gopiga Thanabalasundaram ◽  
Eric Farbman ◽  
Barbara Karp ◽  
Mark Hallett

2015 ◽  
Vol 95 (7) ◽  
pp. 1039-1045 ◽  
Author(s):  
Satoru Amano ◽  
Takashi Takebayashi ◽  
Keisuke Hanada ◽  
Atsushi Umeji ◽  
Kohei Marumoto ◽  
...  

Background and Purpose Spasticity, an aspect of upper motor neuron syndrome, is a widespread problem in patients with stroke. To date, no study has reported the long-term (up to 1 year) outcomes of botulinum toxin (BTX) injection in combination with constraint-induced movement therapy in patients with chronic stroke. In this case report, the long-term (1 year) effects of the combination of BTX type A injection and constraint-induced movement therapy on spasticity and arm function in a patient with chronic stroke and arm paresis are described. Case Description The patient was a 66-year-old man who had had an infarction in the right posterior limb of the internal capsule 4 years before the intervention. At screening, the patient was not able to voluntarily extend his interphalangeal or metacarpophalangeal joints beyond the 10 degrees required for constraint-induced movement therapy. From 12 days after BTX type A injection, the patient received 5 hours of constraint-induced movement therapy for 10 weekdays. Outcomes All outcome measures (Modified Ashworth Scale, Fugl-Meyer Assessment, Action Research Arm Test, and amount of use scale of the Motor Activity Log) improved substantially over the 1-year period (before intervention to 1 year after intervention). Repeat BTX type A injections were not necessary because muscle tone and arm function did not worsen during the observation period. Discussion The improved arm function may have reflected improvements in volitional movements and coordination or speed of movements in the paretic arm as a result of a reduction in spasticity, a reduction of learned nonuse behaviors, or use-dependent plasticity after the combination of BTX type A injection and constraint-induced movement therapy. In addition, the possibility of an influence of the passage of time or the Hawthorne effect cannot be ruled out. If this approach proves useful in future controlled studies, it may reduce the rising medical costs of the treatment of stroke.


2005 ◽  
Vol 63 (2a) ◽  
pp. 221-224 ◽  
Author(s):  
Laura Silveira-Moriyama ◽  
Lilian R. Gonçalves ◽  
Hsin Fen Chien ◽  
Egberto R. Barbosa

To evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment of blepharospasm, a retrospective analysis was conducted from the patients seen at the Movement Disorders Clinic of the Department of Neurology, Hospital das Clínicas, University of São Paulo School of Medicine from 1993 to 2003. A total of 379 treatments with BTX were administered to 30 patients with blepharospasm. Sixty six per cent of the subjects had used oral medication for dystonia and only 15% of them reported satisfactory response to this treatment. Ninety three per cent of the patients showed significant improvement after the first BTX injection. There was no decrement in response when compared the first and the last injection recorded. Adverse effects, mostly minor, developed at least once in 53% of patients. Six patients (20%) discontinued the treatment but there was no case of secondary resistance.


Sign in / Sign up

Export Citation Format

Share Document